BrightSpring Health Services, Inc. (BTSG) · Oct 30, 2026 · Earnings

BrightSpring earnings beat as 2026 guidance rises

Beat — Adjusted EPS $0.54 vs ~$0.45 consensus

BrightSpring earnings beat Q3 revenue expectations by a wide margin, while higher 2026 revenue and EBITDA guidance reinforces its growth story.

BrightSpring is operating as a continuing-operations platform combining specialty pharmacy with home-health and other provider services, while using the Amedisys and LHC branch acquisition to expand its care footprint. The Community Living divestiture has simplified the story toward those two growth engines.

The quarter cleared expectations by a wide margin. Revenue reached $4.213 billion versus a published consensus of roughly $3.88 billion, an approximately 8.6% beat; adjusted EPS was $0.54 versus about $0.45 expected. The filing also shows diluted continuing-operations EPS of $0.46, up from $0.17 a year earlier.

MetricQ3 2026Q3 2025Consensus
Revenue (Financial Highlights)$4.213B (+26.4%)$3.334B~$3.88B
Adjusted EPS (Adjusted EPS reconciliation)$0.54$0.30~$0.45
Adjusted EBITDA (Financial Highlights)$227.8M (+42.0%)$160.4M
Diluted EPS, continuing operations (Income Statement)$0.46$0.17

Growth was broad, but pharmacy remains the main engine. Pharmacy Solutions revenue rose 26% and segment EBITDA increased 43%, while Provider Services revenue grew 31% and segment EBITDA rose 30%. Prescription volume was nearly flat, so the pharmacy result was driven more by revenue and gross profit per script than by dispensing volume.

Management raised the full-year bar rather than merely repeating it. 2026 revenue guidance now stands at $15.9 billion to $16.125 billion, with adjusted EBITDA at $850 million to $860 million; the filing does not provide the prior ranges, so the size of the increase cannot be quantified here. The Amedisys and LHC branches acquisition is expected to contribute about $35 million of 2026 adjusted EBITDA, making the acquired footprint part of the outlook but not the whole explanation for the beat. 〔0〕

The balance sheet also gives the raised outlook more support. Leverage fell to 1.79x from 2.15x at June 30, while nine-month operating cash flow reached $371.2 million and debt declined by roughly $325 million from year-end. That improves financial flexibility as BrightSpring continues investing in provider growth, although the filing still identifies substantial indebtedness and reimbursement pressure as ongoing business risks.

Bottom line: This is more than a routine in-line quarter: BrightSpring delivered a clear earnings and revenue beat, raised its 2026 targets, and showed stronger cash generation and lower leverage. The event materially strengthens the growth-and-execution story heading into 2027.

What to watch next

Q4 earnings and initial 2027 outlook

Original filing on SEC EDGAR

BrightSpring earnings beat as 2026 guidance rises | BTSG Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.